Samsung Medical Center
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
Phase 2
Terminated
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02449655
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02449538
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02448290
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT02448329
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT02447406
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02447380
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02447419
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
Phase 2
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: CHOPDrug: fractionated ICED
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 134
- Registration Number
- NCT02445404
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT02435108
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Completed
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 111
- Registration Number
- NCT02426281
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath